



BioMed Research International

Special Issue on
**Immunotherapy in the Management of Hematologic
Malignancy**

CALL FOR PAPERS

Hematologic malignancies are heterogeneous group of diseases that include Hodgkin and non-Hodgkin lymphoma, multiple myeloma and plasma cell dyscrasias, acute and chronic leukemia, and myelodysplasia. Each year more than a million people die from hematologic malignancies around the world due to the lack of effective therapies. While conventional chemotherapy and high-dose chemotherapy followed by autologous or allogeneic hematopoietic stem cell transplantation have shown significant clinical activity in the management of patients with hematological malignancies chemotherapy-induced toxicities including cytopenia, opportunistic infections as well as transplant-specific toxicities such as donor T cell mediated graft-versus-host disease (GvHD) represent life-threatening complications that limit the application of these approaches to younger and healthier patients. New treatment strategies based upon immunotherapy are now showing promise in treating patients whose disease has relapsed after conventional chemotherapy. The failure of innate immunity (NK, macrophages, etc.) and adaptive immunity (CD4+ and CD8+ T cells) is believed to be responsible for the development of clinically detectable hematological malignancies. Therefore, novel treatment strategies that stimulate the immune system to attack newly generated cancer cells are the primary basis of novel immunotherapy treatments. Several types of immunotherapy that have been found to be clinically useful include (1) cytokines therapy (IL-2, interferons, GM-CSF, IL-12, etc.); (2) therapies based on humanized monoclonal antibodies (Aflibercept targeting CD20 expressing lymphoma, Avelumab targeting HLA-DR expressing hematological cancer cells, etc.); (3) monoclonal antibodies that prevent T cell tolerance (PD-1, PD-L1, CTLA-4, etc.); and/or (4) adoptive T cell therapy engineered to express chimeric antigen receptors (CAR) targeting selective tumors.

We are inviting investigators to contribute original research articles as well as review articles that address the mechanisms by which immunotherapy enhance anticancer response of innate and adaptive immunity.

Authors can submit their manuscripts via the Manuscript Tracking System at <http://mts.hindawi.com/submit/journals/bmri/hematology/imhm/>.

Lead Guest Editor

Mohammad S. Hossain, Emory University, Atlanta, USA
mohammad.s.hossain@emory.edu

Guest Editors

Mohamed L. Salem, Tanta University, Tanta, Egypt
mohamed.labib@science.tanta.edu.eg

Zaid S. Al-Kadhimi, Emory University, Atlanta, USA
zalkadh@emory.edu

Manuscript Due

Friday, 18 March 2016

First Round of Reviews

Friday, 10 June 2016

Publication Date

Friday, 5 August 2016